Bolder Receives Patent for Manufacturing Process

Bolder BioTechnology has been issued a patent for proprietary methods developed by the company to manufacture proteins and modified proteins containing unpaired cysteine.

Adding unpaired cysteine residue to a protein allows targeted modification of the protein with compounds such as polyethylene glycol. Bolder said the process will aid in its development of proprietary, long-acting human protein pharmaceuticals.